NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Takeda Pharmaceutical Stock Down 0.8 % Shares of NYSE TAK opened at $12.95 on Tuesday. The stock has a fifty day moving average price of $13.37 and a 200 day moving average price of $13.90. The ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA capsules to treat adults with mCRC.